MET and neoplasm: The growth of HCC cells after sorafenib resistance has been shown to be ameliorated using dual inhibition of Akt and Met, enhancing the effect of sorafenib, but has not been evaluated in patient-derived xenografts (46), and the HGF/MET axis is also considered to be an important pathway for tumor treatment (47).